About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 2

Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes

Phase 2 Study of SGI-110 in Patients With Higher Risk MDS

NCT02131597•M.D. Anderson Cancer Center

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

High Risk Myelodysplastic Syndrome

Interventions

Guadecitabine

Locations

1

United States

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

November 10, 2014

Primary Completion Date

July 25, 2024

Completion Date

July 25, 2024

Last Updated

July 17, 2025

Related Studies

Active Not RecruitingPhase 2

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

NCT04262843

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia+2 more

COMPLETEDPhase 1/2

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT03047993

Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated Cells+5 more

COMPLETEDPhase 1

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

NCT03263637

Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid Leukemia+9 more

TERMINATEDPhase 1

Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT01636609

Acute Myeloid LeukemiaHigh Risk Myelodysplastic Syndrome

COMPLETEDPhase 1/2

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

NCT01236144

Acute Myeloid LeukaemiaHigh Risk Myelodysplastic Syndrome

Sponsors

Lead Sponsor

M.D. Anderson Cancer Center

Collaborators

National Cancer Institute (NCI)

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions